Skip to main content

Table 2 A Weibull accelerated failure time models of PFS

From: Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France

 

Main analysis

Sensitivity analysis

 

Threshold = 12

Threshold = 5

Threshold = 8

 

Coefficient

σ

Coefficient

σ

Coefficient

σ

High-volume hospital

0.41***

0.136

0.21

0.141

0.33***

0.124

Age

− 0.01**

0.005

− 0.01**

0.005

− 0.01**

0.005

Cancer history

− 0.20

0.154

− v0.24

0.157

− 0.24

0.154

Ascites

− 0.32**

0.145

0.32**

0.149

− 0.34**

0.149

Neoadjuvant chemotherapy

− 0.30**

0.132

− 0.26*

0.135

− 0.29**

0.134

Histology:

 - HGSC

Ref

 

Ref

 

Ref

 

 - LGSC

0.23

0.490

0.28

0.499

0.30

0.495

 - Mucinous

0.14

0.453

0.14

0.467

0.16

0.460

 - Endometrioid

0.15

0.259

0.27

0.256

0.26

0.258

 - Clear cell

− 0.01

0.279

− 0.11

0.286

− 0.16

0.284

 - Unknown

− 0.19

0.209

− 0.09

0.211

− 0.16

0.209

FIGO Stage:

 - I

Ref

 

Ref

 

Ref

 

 - II

− 0.42

0.371

− 0.34

0.375

− 0.35

0.370

 - III

− 0.58**

0.285

− 0.59**

0.292

− 0.58**

0.290

 - IV

− 0.82**

0.319

− 0.85***

0.328

− 0.79***

0.324

Tumor Grade:

 - 1

Ref

 

Ref

 

Ref

 

 - 2

− 0.03

0.420

− 0.09

0.428

− 0.09

0.423

 - 3

− 0.01

0.416

0.06

0.424

0.05

0.420

Intercept

4.77***

0.615

4.60***

0.634

4.65***

0.626

  1. σ: standard deviation / Ref: modality in reference
  2. HGSC High-Grade Serous Carcinoma, LGSC Low-Grade Serous Carcinoma
  3. *, **, ***: significant at 10%, 5%, and 1%, respectively
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us